ATE297751T1 - Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor - Google Patents

Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor

Info

Publication number
ATE297751T1
ATE297751T1 AT01916662T AT01916662T ATE297751T1 AT E297751 T1 ATE297751 T1 AT E297751T1 AT 01916662 T AT01916662 T AT 01916662T AT 01916662 T AT01916662 T AT 01916662T AT E297751 T1 ATE297751 T1 AT E297751T1
Authority
AT
Austria
Prior art keywords
growth factor
inhibitor
combination therapy
epidermis
keratinocyte
Prior art date
Application number
AT01916662T
Other languages
English (en)
Inventor
Penelope Elizabeth Miller
James Dale Moyer
Original Assignee
Pfizer Prod Inc
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22702391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297751(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc, Osi Pharm Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE297751T1 publication Critical patent/ATE297751T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AT01916662T 2000-03-20 2001-03-15 Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor ATE297751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19069700P 2000-03-20 2000-03-20
PCT/US2001/008207 WO2001070255A2 (en) 2000-03-20 2001-03-15 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor

Publications (1)

Publication Number Publication Date
ATE297751T1 true ATE297751T1 (de) 2005-07-15

Family

ID=22702391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916662T ATE297751T1 (de) 2000-03-20 2001-03-15 Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor

Country Status (12)

Country Link
US (3) US20020061304A1 (de)
EP (1) EP1276496B1 (de)
JP (1) JP2003527437A (de)
AT (1) ATE297751T1 (de)
AU (1) AU2001243657A1 (de)
CA (1) CA2403721C (de)
DE (1) DE60111515T2 (de)
ES (1) ES2240430T3 (de)
MX (1) MXPA02009176A (de)
MY (1) MY124799A (de)
TW (1) TWI281402B (de)
WO (1) WO2001070255A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DE602006019074D1 (de) * 2005-04-15 2011-02-03 Einstein Coll Med Vitamin k zur vorbeugung und behandlung von hautausschlag infolge einer anti-egfr-therapie
EP2043685B1 (de) * 2006-07-03 2015-12-23 Genmab A/S Prävention von hautausschlag bei patienten in anti-egfr-therapie
DE102007026877A1 (de) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
EP3782618A4 (de) 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. Verfahren zur vorbeugung oder behandlung von nebenwirkungen einer krebstherapie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
SK281674B6 (sk) * 1993-03-26 2001-06-11 Amgen Inc. Farmaceutická kompozícia na stimuláciu hepatocytov, pneumocytov typu ii, pohárikovitých buniek produkujúcich mucín a iných epitelových buniek
JP3774230B2 (ja) * 1995-02-14 2006-05-10 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ケラチノサイト増殖因子−２
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
AU2001243657A1 (en) 2001-10-03
US20040071697A1 (en) 2004-04-15
US20020061304A1 (en) 2002-05-23
US7402557B2 (en) 2008-07-22
TWI281402B (en) 2007-05-21
EP1276496B1 (de) 2005-06-15
MY124799A (en) 2006-07-31
ES2240430T3 (es) 2005-10-16
EP1276496A2 (de) 2003-01-22
MXPA02009176A (es) 2004-08-12
CA2403721A1 (en) 2001-09-27
WO2001070255A3 (en) 2002-02-28
CA2403721C (en) 2009-06-09
DE60111515T2 (de) 2006-05-11
US20080206257A1 (en) 2008-08-28
JP2003527437A (ja) 2003-09-16
DE60111515D1 (de) 2005-07-21
WO2001070255A2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
DE60111515D1 (de) Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
NO20022065D0 (no) Terapeutisk anvendelse
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200612987A (en) Combination treatment for non-hematologic malignancies
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
ATE320797T1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
ATE245151T1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung
BRPI0416019A (pt) uso de siramesina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, kit, e, método para o tratamento de cáncer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties